#Spain #San Sebastián #Viralgen #Elaaj Bio #CDKL5 Disorder

Advancing Gene Therapy for CDKL5 Deficiency Disorder

In recent news, Viralgen, a prominent contract development and manufacturing organization (CDMO), has announced an important partnership with Elaaj Bio. This collaboration focuses on propelling the development of a gene therapy program aimed at addressing CDKL5 Deficiency Disorder (CDD), a rare and severe neurological condition that primarily impacts children. This partnership combines Viralgen’s expertise in recombinant adeno-associated virus (rAAV) production with Elaaj Bio’s dedication to developing innovative treatments for CDD.

Understanding CDKL5 Deficiency Disorder

CDKL5 Deficiency Disorder is characterized by severe developmental issues and early-onset seizures due to alterations in the CDKL5 gene. The disorder significantly impacts the lives of affected children and their families, highlighting the urgent need for effective treatments. Currently, there is no approved therapy specifically targeting the underlying genetic cause of CDD, making collaborations like this essential.

Partnership Details

As part of this collaboration, Viralgen will utilize its advanced capabilities in AAV vector manufacturing to support the key activities of this investigational gene therapy program. These include process development and optimization, manufacturing at various scales, and thorough analytical characterization.

Early stages of the program have already shown promising results, demonstrating the feasibility of the manufacturing approach. The teams are now focused on scaling up production processes to prepare for larger batch sizes, which is vital for advancing towards clinical trials.

Jimmy Vanhove, the CEO of Viralgen, emphasized the importance of such partnerships in the realm of complex gene therapy programs, particularly in the challenging landscape of rare childhood diseases. By aligning their resources and expertise with Elaaj Bio and the Loulou Foundation, they aim to accelerate the progression of the ELJ-101 gene therapy into clinical development.

The Path Forward

The anticipated timeline involves the initiation of the first clinical trial for ELJ-101 slated for early 2027. Preparations are underway to scale the manufacturing processes to facilitate the eventual clinical trials, reinforcing Viralgen's commitment to bringing innovative solutions to those suffering from CDD.

Russ Addis, the Chief of Pipeline Strategy and Head of Genetic Medicine at the Loulou Foundation, expressed optimism regarding this collaboration, highlighting their mission-driven approach to finding effective therapies for CDKL5 Deficiency Disorder. The Loulou Foundation plays a pivotal role in funding and backing research initiatives aimed at understanding and addressing CDD.

About Viralgen and Elaaj Bio

Viralgen boasts a state-of-the-art facility in San Sebastian, Spain, where it specializes exclusively in AAV-based gene therapies. The organization has established a reputation for high-quality production and consistency, having produced over 1,500 AAV batches since its inception. Conversely, Elaaj Bio, under the Loulou Foundation's umbrella, remains focused on advancing therapeutic research, supporting numerous projects across leading institutions to combat CDKL5 Deficiency Disorder effectively.

Conclusion

This collaboration heralds a significant step forward in the search for viable gene therapies for CDKL5 Deficiency Disorder. With the combined strengths of both organizations, there is hope that ELJ-101 will pave the way for much-needed treatments for affected families.

For further information on Viralgen and their initiatives, visit Viralgen's website. To learn more about the work done by Elaaj Bio and the Loulou Foundation, check out Loulou Foundation's website.